L E Friberg

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi Mechanistic models for myelosuppression
    Lena E Friberg
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Invest New Drugs 21:183-94. 2003
  2. ncbi An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment
    L E Friberg
    Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 85:409-17. 2009
  3. ncbi Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
    Lena E Friberg
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    J Clin Oncol 20:4713-21. 2002
  4. ncbi Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia
    L E Friberg
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 86:84-91. 2009
  5. ncbi Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
    Lena E Friberg
    Department of Pharmaceutical Biosciences, Uppsala University, SE 75124, Uppsala, Sweden
    Invest New Drugs 28:744-53. 2010
  6. ncbi Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
    Lena E Friberg
    School of Pharmacy, University of Queensland, Brisbane, Australia
    Br J Clin Pharmacol 61:177-90. 2006
  7. ncbi Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC)
    L E Friberg
    Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, SE 751 23 Uppsala, Sweden
    Eur J Clin Pharmacol 56:567-74. 2000
  8. ncbi Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats
    L E Friberg
    Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Uppsala, Sweden
    J Pharmacol Exp Ther 295:734-40. 2000
  9. ncbi The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach
    Lena E Friberg
    School of Pharmacy, University of Queensland, Brishane, Australia
    J Pharmacokinet Pharmacodyn 32:571-605. 2005
  10. ncbi Pharmacokinetic/pharmacodynamic modelling in oncological drug development
    Mats O Karlsson
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    Basic Clin Pharmacol Toxicol 96:206-11. 2005

Detail Information

Publications25

  1. ncbi Mechanistic models for myelosuppression
    Lena E Friberg
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Invest New Drugs 21:183-94. 2003
    ....
  2. ncbi An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment
    L E Friberg
    Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 85:409-17. 2009
    ..This quantitative mechanism-based model is the first to describe prolactin release in patients, and it confirms that paliperidone and risperidone have similar potencies for prolactin release...
  3. ncbi Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
    Lena E Friberg
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    J Clin Oncol 20:4713-21. 2002
    ..To develop a semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression through drug-specific parameters and system-related parameters, which are common to all drugs...
  4. ncbi Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia
    L E Friberg
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Clin Pharmacol Ther 86:84-91. 2009
    ..Although simulations indicated that the post hoc probability of success of the performed trials was low to moderate, these analyses demonstrated that 5 and 10 mg twice-daily (b.i.d.) doses of asenapine have similar efficacy...
  5. ncbi Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
    Lena E Friberg
    Department of Pharmaceutical Biosciences, Uppsala University, SE 75124, Uppsala, Sweden
    Invest New Drugs 28:744-53. 2010
    ..To investigate the potential of a model for chemotherapy-induced myelosuppression to predict the full time-course of myelosuppression in patients based on rat data...
  6. ncbi Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
    Lena E Friberg
    School of Pharmacy, University of Queensland, Brisbane, Australia
    Br J Clin Pharmacol 61:177-90. 2006
    ....
  7. ncbi Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC)
    L E Friberg
    Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, SE 751 23 Uppsala, Sweden
    Eur J Clin Pharmacol 56:567-74. 2000
    ..The major dose-limiting toxicity of DMDC is haematological depression, particularly neutropenia, and therefore quantitative exposure-toxicity relationships for DMDC are warranted...
  8. ncbi Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats
    L E Friberg
    Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Uppsala, Sweden
    J Pharmacol Exp Ther 295:734-40. 2000
    ..A posterior predictive check as well as predictions into a new data set showed that our model could well predict the schedule-dependent leukopenic effects of 5-fluorouracil...
  9. ncbi The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach
    Lena E Friberg
    School of Pharmacy, University of Queensland, Brishane, Australia
    J Pharmacokinet Pharmacodyn 32:571-605. 2005
    ..These findings suggest charcoal administration is potentially beneficial after citalopram overdose. The methodology explored seems promising for exploring the dose-exposure relationship in the toxicological settings...
  10. ncbi Pharmacokinetic/pharmacodynamic modelling in oncological drug development
    Mats O Karlsson
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    Basic Clin Pharmacol Toxicol 96:206-11. 2005
    ....
  11. ncbi Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
    Emma K Hansson
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 751 24 Uppsala, Sweden
    Cancer Chemother Pharmacol 65:839-48. 2010
    ..The objective of this study was to evaluate and compare magnitudes of IOV and IIV in myelosuppression model parameters across six different anti-cancer drug treatments...
  12. ncbi Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool
    Johan E Wallin
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Ther Drug Monit 31:457-66. 2009
    ..The appropriateness of targets was not investigated in this study. The Bayesian dosing adjustment tool and suggested dose recommendations need to be evaluated in a prospective study before they can be applied in the clinical setting...
  13. ncbi A tool for neutrophil guided dose adaptation in chemotherapy
    Johan E Wallin
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Comput Methods Programs Biomed 93:283-91. 2009
    ..In the dosing tool the user provides neutrophil measures from a previous treatment course and request for the dose that results in a desired nadir in the upcoming course through a Bayesian estimation procedure...
  14. ncbi Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model
    Elisabet I Nielsen
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    Antimicrob Agents Chemother 55:1571-9. 2011
    ..Adding data from dynamic experiments in the estimation improved the model fit for cefuroxime and vancomycin, indicating some differences in sensitivity to experimental conditions among the antibiotics studied...
  15. ncbi Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS
    Britt Jansson
    Division of Pharmacokinetics and Drug Therapy, Department of Biopharmaceutical Sciences, Biomedicum, Box 591, SE 75124 Uppsala, Sweden
    J Pharm Biomed Anal 49:760-7. 2009
    ..4% and accuracy <+/-8.1%. The quick sample work-up method allows for determination of colistin A and B in clinical samples without causing hydrolysis of the prodrug colistin methanesulfonate (CMS)...
  16. ncbi Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM
    K J F Petersson
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 751 24 Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 37:493-506. 2010
    ..When computational runtime seriously affects the usefulness of a model we suggest evaluating this approach for repetitive elements of model building and evaluation such as covariate inclusions or bootstraps...
  17. ncbi Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information
    Johan E Wallin
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Basic Clin Pharmacol Toxicol 106:234-42. 2010
    ....
  18. ncbi Evaluation of IPPSE, an alternative method for sequential population PKPD analysis
    B D Lacroix
    Pharmacometrics Group, Dept of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 39:177-93. 2012
    ..The IPPSE method is a promising alternative for PKPD analysis, combining the advantages of the SIM (higher precision and lower bias of parameter estimates) and the IPP (shorter run time) methods...
  19. ncbi In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients
    E Jonsson
    Division of Clinical Pharmacology, Akademiska Hospital, SE 751 85, Uppsala, Sweden
    Cancer Lett 162:193-200. 2001
    ..The results show a feasibility of using tumour cells directly from patients in the hollow-fibre rat model...
  20. ncbi Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients
    Stefanie Hennig
    School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australian
    Clin Pharmacokinet 45:1099-114. 2006
    ..The ultimate goals were to determine the relative bioavailability between the two oral formulations (capsules vs oral solution) and to optimise dosing regimens in these patients...
  21. ncbi Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model
    Lena E Friberg
    Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden
    Eur J Pharm Sci 25:163-73. 2005
    ..The prolonged schedules of CHS 828 were therefore associated with greater antitumour effects than single doses of the same total exposure...
  22. ncbi Activated charcoal decreases the risk of QT prolongation after citalopram overdose
    Geoffrey K Isbister
    Menzies School of Health Research, Charles Darwin University, Darwin, Australia
    Ann Emerg Med 50:593-600, 600.e1-46. 2007
    ..We determine whether single-dose activated charcoal (SDAC) administration after citalopram overdose reduces the proportion of patients developing abnormal QT prolongation...
  23. ncbi Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose
    Geoffrey K Isbister
    Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
    Intensive Care Med 32:1060-5. 2006
    ..To develop guidelines for the management of QT prolongation after citalopram overdose, including decontamination with single-dose activated charcoal (SDAC) and cardiac monitoring...
  24. ncbi Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 96:1585-92. 2004
    ..We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38...
  25. ncbi Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:2719-26. 2007
    ..The purpose of this study was to determine the effects of cigarette smoking on the pharmacokinetics and adverse effects of irinotecan...